By Memorandum Order entered by The Honorable Colm F. Connolly in Pharmacyclics LLC et al. v. Cipla Limited, et al., Civil Action No. 18-192-CFC/CJB (D.Del. November 10, 2020) (Consolidated), the Court granted Plaintiffs’ request to preclude Defendant Sandoz from maintaining its theory that U.S. Patent No. 10,106,548 (“the ‘548 patent”) is invalid

By Memorandum Order entered by The Honorable Richard G. Andrews in HSM Portfolio LLC, et al. v. Elpida Memory Inc., et al., Civil Action No. 11-770-RGA (D.Del., February 11, 2016), the Court, among other things, granted Defendant’s motion to strike (D.I. 1049)  with respect to the new infringement theory for the ‘949 patent raised

In Biovail Laboratories Int’l SRL v. Cary Pharmaceuticals Inc., C.A. No. 09-605-JJF-LPS (D.Del., May 26, 2010), Judge Stark denied Defendant Cary Pharmaceuticals ("Cary") motion to strike plaintiff Biovail expert’s supplemental declaration that was submitted by plaintiff in connection with the filing of its answering brief on claim construction.  However, given plaintiff’s conduct in submitting its